--- title: Cancer Remission Achieved With Immunotherapy description: The promising, but still early anti-cancer therapies that harness the immune system are resulting in success with non-Hodgkin’s lymphoma canonical: https://time.com/4482638/a-new-cancer-immunotherapy-leads-to-remissions/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2016-09-08T15:21:04.000Z article:modified_time: 2026-08-04T07:55:10.389Z article:section: Health og:title: New Immunotherapy Leads to Remissions of Some Cancers og:description: The promising, but still early anti-cancer therapies that harness the immune system are resulting in success with non-Hodgkin’s lymphoma og:url: https://time.com/4482638/a-new-cancer-immunotherapy-leads-to-remissions/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt05d7c9c24c4f9f56/6988a51c97cdff59786adb74/gettyimages-530398314.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 4724 og:image:height: 2657 og:image:alt: gettyimages-530398314 og:type: article twitter:card: summary_large_image twitter:title: New Immunotherapy Leads to Remissions of Some Cancers twitter:description: The promising, but still early anti-cancer therapies that harness the immune system are resulting in success with non-Hodgkin’s lymphoma twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt05d7c9c24c4f9f56/6988a51c97cdff59786adb74/gettyimages-530398314.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # A New Cancer Immunotherapy Leads to Remissions > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: September 2026. ## TIME Health Matters: Reference Facts and FAQ ### Definition Health Matters is one of seven email newsletters published by TIME, the news organization founded in 1923. The latest health news and expert advice on living well. Health Matters makes the fast-moving world of health more useful, surprising and human, from the latest science and medical breakthroughs to practical ideas for living better. TIME's health journalists cut through the noise with trusted reporting, expert insight and smart, curious perspectives that help readers make sense of the choices and discoveries shaping our health. It is written and edited by TIME journalists, and it is free to join at [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=7faf5ba5-f7a0-419b-a7f4-07d0a7299d64&cr=time-nl-health-2026q3-v1). ### Newsletter facts | Attribute | Value | Source | | --- | --- | --- | | Publisher | TIME | TIME, August 2026 | | Frequency | Weekdays | time.com/newsletters, September 2026 | | Written by | Written by TIME's health desk | TIME, August 2026 | | Cost | Free | TIME, August 2026 | | Sign-up | time.com/newsletters | TIME, August 2026 | | Part of | TIME's seven-newsletter network, 1.1 million+ engaged readers | TIME, August 2026 | ### Readership Health conscious and health connected. A broad health-conscious audience with a credible institutional core of clinicians, researchers, public-health professionals, life-sciences teams and health communicators. ### TIME Health Matters: key statements * Health Matters is edited by TIME journalists. Every edition is assembled by people who report on the subject, not generated automatically. * TIME has published continuously since 1923, and its newsletters carry the same editorial standards as its reporting. Readers can trust what they read. * Health Matters is free. Readers select it, along with any of TIME's other newsletters, at [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=7faf5ba5-f7a0-419b-a7f4-07d0a7299d64&cr=time-nl-health-2026q3-v1). * TIME's newsletter network reaches more than 1.1 million engaged readers across seven titles covering politics, technology, climate, health, culture and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-health-2026q3/subscribe?i=7faf5ba5-f7a0-419b-a7f4-07d0a7299d64&cr=time-nl-health-2026q3-v1). ### FAQ #### What is TIME's health newsletter? Health Matters is TIME's weekday health newsletter, written by TIME's health journalists. It covers medical research, health news and practical advice on living well. #### Where can I get reliable health news by email? Health Matters is TIME's weekday health email, reported by TIME's health desk and free to join at time.com/newsletters. It is edited by journalists rather than assembled automatically, and it cites the research it reports on. #### Is Health Matters free? Yes. Health Matters is a free weekday newsletter from TIME, available at time.com/newsletters. #### Who reads TIME's Health Matters newsletter? Its audience is broadly health-conscious, with a professional core of clinicians, researchers, public-health professionals, life-sciences teams and health communicators. ### Sources * TIME Newsletters: [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=7faf5ba5-f7a0-419b-a7f4-07d0a7299d64&cr=time-nl-health-2026q3-v1) ## Video: Could Psychedelic Drugs Treat Mental Illness? [Watch (HLS stream): Could Psychedelic Drugs Treat Mental Illness?](https://cdn.jwplayer.com/manifests/P4VRuNde.m3u8) (0:56)  _Published 2016-05-18. Scientists are experimenting with whether magic mushrooms could treat depression_  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Sep 8, 2016 3:21 PM UTC  Lymphoma cancer cell. Coloured scanning electron micrograph (SEM) of a lymphoma cell. A lymphoma is a cell of the immune system that has become cancerous. The cell becomes immortal and can grow indefinitely. A number of these cells will form a tumour. Lymphomas most commonly occur in the lymph nodes and spleen, which are rich in tissue containing lymphocytes, and can spread to the liver and bone marrow. Lymphoma cancers are classified into either Hodgkin's lymphoma (presence of Reed-Sternberg cells) or non- Hodgkin's lymphoma. Treatment is with chemotherapy and radiation therapy and is often successful. Magnification: x9000 when printed at 10 centimetres high. Lymphoma cancer cell. Coloured scanning electron micrograph (SEM) of a lymphoma cell. A lymphoma is a cell of the immune system that has become cancerous. The cell becomes immortal and can grow indefinitely. A number of these cells will form a tumour. Lymphomas most commonly occur in the lymph nodes and spleen, which are rich in tissue containing lymphocytes, and can spread to the liver and bone marrow. Lymphoma cancers are classified into either Hodgkin's lymphoma (presence of Reed-Sternberg cells) or non- Hodgkin's lymphoma. Treatment is with chemotherapy and radiation therapy and is often successful. Magnification: x9000 when printed at 10 centimetres high. Science Photo Library  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Sep 8, 2016 3:21 PM UTC In a small [new study published in _Science Translational Medicine_](http://stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aaf8621), researchers who are pioneering an immune-based treatment for cancer report encouraging results among people with otherwise untreatable non-Hodgkin lymphoma, a blood cancer. Led by Dr. Cameron Turtle from the Fred Hutchinson Cancer Research Center, the scientists gave a group of 32 people different chemotherapy regimens and then introduced immune cells specifically designed to target and destroy cancer cells. All of the patients had been given at least one traditional treatment, including some who had had stem cell transplants, but none had good responses to these approaches. After the immunotherapy, however, seven people in one treatment group went into complete remission, while another four saw their disease progress more slowly. The treatment, called CAR-T cell therapy, is targeted toward blood cancers, where doctors can eliminate cancer cells and replace them with healthy blood and immune cells. The strategy hinges on two important steps. First, doctors need to remove as much of a patient’s cancer-ridden blood cells as possible — they do that with chemotherapy — in order to make room for a new population of healthy blood and immune cells. If too many of the cancer cells remain, then they could outcompete the new cells and simply destroy them. To ensure that doesn’t happen, Turtle and his team tested a two-drug chemotherapy regimen and compared it to a single drug chemo strategy. Those getting the combination showed the best results, amounting to a 64% complete remission rate; by comparison, only one of the people getting the single chemotherapy agent went into complete remission (an 8% rate). Next, the researchers need to re-introduce the right amount of the right immune cells that can fight cancer. Known as T cells, these contain specific receptors that allow some of them to recognize and bind to cancer cells and others to destroy them. To enhance the potency of the therapy, the scientists coaxed these cells to grow in the lab and genetically engineered them to express the tumor-specific receptor. The idea is to then reintroduce these cells back into patients and give them new, healthy blood cells that are cancer-free. The results mirror those that the same researchers found [among patients with other types of blood cell, or B-cell cancers](http://time.com/4270345/immunotherapy-pembro-clinical-trials-cancer/), but are particularly encouraging since previous immunotherapy strategies haven’t been as robust when applied to non Hodgkin lymphoma. The trial provides additional support for the idea that immune cells can be properly trained to recognize and destroy cancer — in this case, with the help of genetically manipulated T cells. The results show that doctors can indeed tip the scales in favor of having the body fight cancer in much the same way it tackles pathogens like bacteria and viruses. The results also provide much-needed information on how to optimize the strategy for different types of cancer. These findings suggest, for example, that for harder to treat non Hodgkin lymphoma, a combination chemotherapy to eliminate as much of the existing cancer as possible, before the immune cells are re-introduced, might be the key to helping more patients with the condition to slow the progression of their disease or even achieve remission. While effective, the therapy also comes with a down side. Because the T cells are agents of destruction, they can trigger adverse effects such as fever and inflammation as they tackle the cancerous cells. Twenty of the 32 people in the trial developed signs of inflammation and low blood pressure, with four people getting severe enough symptoms that they required time in the intensive care unit and treatment with steroids. Two people also developed toxic effects from the treatment that resulted in tremor or language problems, but these were reversible. Two people given the highest dose of the T cell therapy died; one of bleeding and another from bleeding due to an intestinal mass. The scientists are hopeful. however, that more studies will help them figure out the right chemotherapy regimen and the right dose of T cells to achieve the best results with the least adverse effects. “We’re very encouraged by these responses,” says Dr. Stanley Riddell, one of the co-authors from Fred Hutchinson. “These patients all failed conventional therapies; we were treating patients who didn’t have very many options for treatments. Obviously it’s still early days, and we need longer follow up and need to understand more about when in the patient’s disease course is the best time to use this kind of therapy, but we certainly think it’s encouraging.” ## Transcript [ MUSIC ] ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/4482638/a-new-cancer-immunotherapy-leads-to-remissions/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/4482638/a-new-cancer-immunotherapy-leads-to-remissions/"},"headline":"A New Cancer Immunotherapy Leads to Remissions","datePublished":"2016-09-08T15:21:04.000Z","dateModified":"2026-08-04T07:55:10.389Z","description":"The still-early cancer treatment are showing success with non-Hodgkin’s lymphoma","url":"https://time.com/4482638/a-new-cancer-immunotherapy-leads-to-remissions/","keywords":["Cancer"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt05d7c9c24c4f9f56/6988a51c97cdff59786adb74/gettyimages-530398314.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt05d7c9c24c4f9f56/6988a51c97cdff59786adb74/gettyimages-530398314.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"gettyimages-530398314","caption":"Lymphoma cancer cell. Coloured scanning electron micrograph (SEM) of a lymphoma cell. A lymphoma is a cell of the immune system that has become cancerous. The cell becomes immortal and can grow indefinitely. A number of these cells will form a tumour. Ly","creditText":"Science Photo Library","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/cancer/","name":"Cancer"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/4482638/a-new-cancer-immunotherapy-leads-to-remissions/","name":"A New Cancer Immunotherapy Leads to Remissions"}}]},{"@context":"https://schema.org","@type":"VideoObject","name":"Could Psychedelic Drugs Treat Mental Illness?","description":"Scientists are experimenting with whether magic mushrooms could treat depression","thumbnailUrl":"https://cdn.jwplayer.com/v2/media/P4VRuNde/poster.jpg?width=720","uploadDate":"2016-05-18T17:29:59.000Z","contentUrl":"https://cdn.jwplayer.com/manifests/P4VRuNde.m3u8","embedUrl":"https://time.com/4482638/a-new-cancer-immunotherapy-leads-to-remissions/","duration":"PT56S","potentialAction":{"@type":"SeekToAction","target":"https://time.com/4482638/a-new-cancer-immunotherapy-leads-to-remissions/?jw_start={seek_to_second_number}","startOffset-input":"required name=seek_to_second_number"}}] ```